Skip

SENSCIS trial: additional analysis presented at Virtual EULAR 2020

Nuove analisi dello studio SENSCIS (Nintedanib in SSc-ILD) presentate a European League Against Rheumatism (EULAR) 2020 Virtual Congress – Slide kit

banner-articoli

 

Risultati di efficacia e sicurezza per nintedanib da ulteriori analisi dello studio SENSCIS:

  • Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and normal versus elevated C-reactive protein (CRP) at baseline

  • Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing extents of skin fibrosis

  • Is the rate of lung function decline the same in patients with systemic sclerosis-associated ILD (SSc-ILD) who experience weight loss?

  • Correlation between progression of skin fibrosis and progression of interstitial lung disease in patients with SSc-ILD

  • Is there a difference between the sexes in the rate of progression of systemic sclerosis-associated ILD (SSc-ILD)?

Visualizza contenuto

ARTICOLI CORRELATI

LEGGI
img-card
PRATICA CLINICA

Nintedanib reduces lung function decline in patients with systemic sclerosis-associated interstitial lung disease: results of the SENSCIS® trial

Risultati principali dello studio clinico di fase III SENSCIS® che ha valutato efficacia e sicurezza di nintedanib in pazienti con malattia interstiziale polmonare associata a sclerosi sistemica (SSc-ILD) - Slide kit
LEGGI
LEGGI
img-card
PRATICA CLINICA

SENSCIS subgroups analyses by SSc subset, by ATA status, by MMF use and by corticosteroid use

Analisi per sottogruppi dello studio SENSCIS (Nintedanib nei pazienti con SSc-ILD) – Slide kit
LEGGI
LEGGI
img-card
PRATICA CLINICA

The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements

Primo consensus di esperti per l’identificazione e gestione dei pazienti con malattia polmonare insterstiziale associata a sclerosi sistemica (SSc-ILD) – Slide Kit
LEGGI